Zegarra-Moran O - Search Results

1

Correction of G551D-CFTR transport defect in epithelial monolayers by genistein but not by CPX or MPB-07.

Zegarra-Moran O, Romio L, Folli C, Caci E, Becq F, Vierfond JM, Mettey Y, Cabrini G, Fanen P, Galietta LJ. Zegarra-Moran O, et al. Br J Pharmacol. 2002 Oct;137(4):504-12. doi: 10.1038/sj.bjp.0704882. Br J Pharmacol. 2002. PMID: 12359632 Free PMC article.

2

IL-4 is a potent modulator of ion transport in the human bronchial epithelium in vitro.

Galietta LJ, Pagesy P, Folli C, Caci E, Romio L, Costes B, Nicolis E, Cabrini G, Goossens M, Ravazzolo R, Zegarra-Moran O. Galietta LJ, et al. J Immunol. 2002 Jan 15;168(2):839-45. doi: 10.4049/jimmunol.168.2.839. J Immunol. 2002. PMID: 11777980

3

CFTR activation in human bronchial epithelial cells by novel benzoflavone and benzimidazolone compounds.

Caci E, Folli C, Zegarra-Moran O, Ma T, Springsteel MF, Sammelson RE, Nantz MH, Kurth MJ, Verkman AS, Galietta LJ. Caci E, et al. Am J Physiol Lung Cell Mol Physiol. 2003 Jul;285(1):L180-8. doi: 10.1152/ajplung.00351.2002. Epub 2003 Mar 21. Am J Physiol Lung Cell Mol Physiol. 2003. PMID: 12651632 Free article.

4

Altered channel gating mechanism for CFTR inhibition by a high-affinity thiazolidinone blocker.

Taddei A, Folli C, Zegarra-Moran O, Fanen P, Verkman AS, Galietta LJ. Taddei A, et al. FEBS Lett. 2004 Jan 30;558(1-3):52-6. doi: 10.1016/S0014-5793(04)00011-0. FEBS Lett. 2004. PMID: 14759515 Free article.

5

Antihypertensive 1,4-dihydropyridines as correctors of the cystic fibrosis transmembrane conductance regulator channel gating defect caused by cystic fibrosis mutations.

Pedemonte N, Diena T, Caci E, Nieddu E, Mazzei M, Ravazzolo R, Zegarra-Moran O, Galietta LJ. Pedemonte N, et al. Mol Pharmacol. 2005 Dec;68(6):1736-46. doi: 10.1124/mol.105.015149. Epub 2005 Sep 8. Mol Pharmacol. 2005. PMID: 16150931

6

Block of CFTR-dependent chloride currents by inhibitors of multidrug resistance-associated proteins.

Diena T, Melani R, Caci E, Pedemonte N, Sondo E, Zegarra-Moran O, Galietta LJ. Diena T, et al. Eur J Pharmacol. 2007 Apr 10;560(2-3):127-31. doi: 10.1016/j.ejphar.2007.01.051. Epub 2007 Feb 3. Eur J Pharmacol. 2007. PMID: 17320853 Free PMC article.

7

Evidence for direct CFTR inhibition by CFTR(inh)-172 based on Arg347 mutagenesis.

Caci E, Caputo A, Hinzpeter A, Arous N, Fanen P, Sonawane N, Verkman AS, Ravazzolo R, Zegarra-Moran O, Galietta LJ. Caci E, et al. Biochem J. 2008 Jul 1;413(1):135-42. doi: 10.1042/BJ20080029. Biochem J. 2008. PMID: 18366345

8

Mutation-specific potency and efficacy of cystic fibrosis transmembrane conductance regulator chloride channel potentiators.

Caputo A, Hinzpeter A, Caci E, Pedemonte N, Arous N, Di Duca M, Zegarra-Moran O, Fanen P, Galietta LJ. Caputo A, et al. J Pharmacol Exp Ther. 2009 Sep;330(3):783-91. doi: 10.1124/jpet.109.154146. Epub 2009 Jun 2. J Pharmacol Exp Ther. 2009. PMID: 19491324 Free PMC article.

9

Modulation of cystic fibrosis transmembrane conductance regulator (CFTR) activity and genistein binding by cytosolic pH.

Melani R, Tomati V, Galietta LJ, Zegarra-Moran O. Melani R, et al. J Biol Chem. 2010 Dec 31;285(53):41591-6. doi: 10.1074/jbc.M110.166850. Epub 2010 Oct 25. J Biol Chem. 2010. PMID: 20974851 Free PMC article.

10

Pharmacological analysis of epithelial chloride secretion mechanisms in adult murine airways.

Gianotti A, Ferrera L, Philp AR, Caci E, Zegarra-Moran O, Galietta LJ, Flores CA. Gianotti A, et al. Among authors: zegarra moran o. Eur J Pharmacol. 2016 Jun 15;781:100-8. doi: 10.1016/j.ejphar.2016.04.007. Epub 2016 Apr 7. Eur J Pharmacol. 2016. PMID: 27063443

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

76 results

Search Page

Filters